Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Celator(R) Pharmaceuticals Receives Notice of Allowance on U.S. Patent for CombiPlex(R) Technology Platform

Abstract:
Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlex® technology platform (U.S. patent application 10/417,631), the basis for the company's product pipeline which includes two clinical-stage products for acute myeloid leukemia and colorectal cancer.

Celator(R) Pharmaceuticals Receives Notice of Allowance on U.S. Patent for CombiPlex(R) Technology Platform

Princeton, NJ | Posted on April 12th, 2010

CombiPlex is a unique approach in the development of combination drug therapies used for treating cancer. It is the only approach using drug carriers to deliver synergistic ratios of cancer drug combinations. In contrast to conventional combination chemotherapies, Celator recognized that different ratios of the same two (or more) drugs can be synergistic, additive and even antagonistic. CombiPlex identifies a synergistic ratio of the drugs and locks this ratio in nano-scale (about 100 times smaller than a red blood cell) carriers that are able to deliver and maintain the synergistic drug ratio after injection in patients. This extended delivery of a synergistic ratio of drugs is intended to increase the effectiveness of the combination and improve clinical outcomes.

"This broad allowance protects our ability to utilize the CombiPlex platform with a wide variety of antineoplastic agents, opening up numerous potential combinations for investigation and possible commercialization," said Dr. Lawrence Mayer, president and head or research at Celator Pharmaceuticals.

Celator received similar patent protection for CombiPlex from the European Patent Office in 2006. The U.S. patent will extend until at least 2024.

"Extending patent protection of CombiPlex to the US strengthens our intellectual property portfolio as we advance our pipeline of cancer therapies and collaborative programs with other pharmaceutical companies," said Scott Jackson, CEO of Celator Pharmaceuticals. "The technology has already yielded promising clinical data. In December, we reported encouraging interim data from the first of two randomized Phase 2 clinical studies in patients with Acute Myeloid Leukemia treated with our lead drug, CPX-351, and we will report additional efficacy and safety data with CPX-351 later this year."

####

About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

For more information, please click here

Copyright © PRWeb

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Thanks for the memory: NIST takes a deep look at memristors January 20th, 2018

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Ultra-thin optical fibers offer new way to 3-D print microstructures: Novel approach lays groundwork for using 3-D printing to repair tissue in the body January 17th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Announcements

Thanks for the memory: NIST takes a deep look at memristors January 20th, 2018

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Patents/IP/Tech Transfer/Licensing

IBM Breaks Records to Top U.S. Patent List for 25th Consecutive Year: IBM Inventors Receive Record 9,043 Patents in 2017 in Areas such as Artificial Intelligence, Cloud, Blockchain, Cybersecurity and Quantum Computing January 11th, 2018

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

Chinese market opens up for Carbodeon nanodiamonds: Carbodeon granted Chinese Patent for Nanodiamond-containing Thermoplastic Thermal Compounds December 4th, 2017

Picosun’s ALD nanolaminates improve lifetime and reliability of electronic circuit boards October 24th, 2017

Nanobiotechnology

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Ultra-thin optical fibers offer new way to 3-D print microstructures: Novel approach lays groundwork for using 3-D printing to repair tissue in the body January 17th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project